Katherine Poinsatte, PhD,  Science writer—

Intravenous immunoglobulin (IVIg) therapy can reduce relapses and lessen long-term disability in people with eosinophilic granulomatosis with polyangiitis (EGPA), a rare form of ANCA-associated vasculitis (AAV), a study from Italy has found. At patients’ one-year follow-up after IVIg treatment, reductions in peripheral neuropathy — damage to nerves outside…

Enrollment is now open for a small clinical trial designed to test dose-escalating doses of experimental cell therapy NKX019 in people with ANCA-associated vasculitis (AAV) and other autoimmune disorders. Called Ntrust-2, the study will assess the therapy’s safety and ability to promote long-term disease remissions in an initial group…

Treatment with rituximab in children with ANCA-associated vasculitis (AAV) is at least non-inferior to the use of cyclophosphamide at inducing disease remission or low disease activity among pediatric patients, according to data from a large international observational study. The researchers noted that rituximab treatment was associated with greater…

The long-term use of Nucala (mepolizumab) reduces disease activity and the need for standard glucocorticoids, while improving survival, in people with eosinophilic granulomatosis with polyangiitis (EGPA), the rarest type of ANCA-associated vasculitis (AAV). These are the findings of a real-world study in Japan that compared outcomes between 37…